natgillin/translations-raw huggingface dataset:
If necessary, Cosentyx may be stored unrefrigerated for a single period of up to 4 days at room temperature, not above 30°C.
Če je potrebno, je zdravilo Cosentyx mogoče hraniti izven hladilnika v enkratnem največ 4-dnevnem obdobju pri sobni temperaturi, ki ne presega 30 °C.
Serious infections were reported in 1.2% of patients treated with secukinumab (0.015 per patient-year of follow-up).
O resnih okužbah so poročali pri 1,2 % bolnikov, ki so prejemali sekukinumab (0,015 na enoto bolnik-leto spremljanja).
What you need for your injection:
Kaj potrebujete pri injiciranju:
About half of the treatment-emergent anti-drug antibodies were neutralising, but this was not associated with loss of efficacy or pharmacokinetic abnormalities.
Med protitelesi, ki so bila usmerjena proti zdravilu in so se razvila zaradi zdravljenja, je bilo približno pol nevtralizirajočih protiteles, vendar to ni zmanjšalo učinkovitosti zdravila ali povzročilo farmakokinetičnih nepravilnosti.
Prepare the required number of syringes (2 syringes for the 300 mg dose).
Pripravite potrebno število brizg (2 brizgi za odmerek 300 mg).
Cosentyx is used to treat a skin condition called “plaque psoriasis”, which causes inflammation affecting the skin.
Zdravilo Cosentyx uporabljamo za zdravljenje kožne bolezni, ki jo imenujemo "psoriaza s plaki" (psoriaza v obliki plošč), le-ta povzroča vnetje, ki prizadene kožo.
Table 2 Summary of PASI 50/75/90/100 & IGA mod 2011 “clear” or “almost clear” clinical response in psoriasis studies 1, 3 and 4 (ERASURE, FEATURE and JUNCTURE)
Preglednica 2 Pregled kliničnih odzivov PASI 50/75/90/100 & IGA mod 2011 "brez znakov" oziroma "skoraj brez znakov"v 1., 3. in 4. študiji psoriaze (v študijah ERASURE, FEATURE in JUNCTURE)
Of the 2,403 patients who were included in the placebo-controlled studies, 79% were biologic-naive, 45% were non-biologic failures and 8% were biologic failures (6% were anti-TNF failures, and 2% were anti-p40 failures).
Med 2.403 bolniki, ki so bili vključeni v s placebom kontrolirane študije, jih 79 % pred tem še ni prejemalo bioloških zdravil, pri 45 % je bilo neuspešno predhodno zdravljenje, ki ni vključevalo bioloških zdravil, pri 8 % pa je bilo neuspešno predhodno zdravljenje z biološkimi zdravili (pri 6 % z zaviralci TNF in pri 2 % z zdravili proti podenoti p40).
The most frequently reported adverse drug reactions (ADRs) are upper respiratory tract infections (most frequently nasopharyngitis, rhinitis).
Najbolj pogosti neželeni učinki, o katerih so poročali, so okužbe zgornjih dihal (najpogosteje so poročali o nazofaringitisu in rinitisu).
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Zdravilo Cosentyx je indicirano za zdravljenje aktivnega ankilozirajočega spondilitisa pri odraslih z nezadostnim odzivom na konvencionalno terapijo.
ASAS 20 response, %
odziv ASAS 20, %
Detailed instructions for use are provided in the package leaflet.
Podrobna navodila za uporabo zdravila lahko najdete v priloženem Navodilu za uporabo.
Secukinumab 300 mg was superior to placebo at week 12 as assessed by significant improvement from baseline in both the PSSI 90 response (52.9% versus 2.0%) and IGA mod 2011 0 or 1 scalp only response (56.9% versus 5.9%).
Sekukinumab 300 mg je bil po 12 tednih boljši od placeba, kar se je pokazalo s pomembnim izboljšanjem od izhodišča tako odziva PSSI 90 (52,9 % v primerjavi z 2,0 %) kot odziva z oceno IGA mod 2011 0 ali 1 (56,9 % v primerjavi s 5,9 %).
In PsA study 1 and PsA study 2, efficacy was maintained up to week 104.
V PsA študiji 1 in 2 se je učinkovitost zdravila ohranjala do konca 104. tedna.
Based on clinical response, the dose can be increased to 300 mg.
Na osnovi kliničnega odziva je mogoče odmerek zvišati na 300 mg.
The needle cap of the syringe may contain dry rubber (latex), which should not be handled by persons sensitive to this substance.
Pokrovček igle pri tej brizgi lahko vsebuje suho gumo (lateks), zato osebe, ki so preobčutljive na lateks, ne smejo rokovati z navedenim pokrovčkom.
Withdraw slightly more than 1.0 ml sterile water for injections into a 1 ml graduated disposable syringe and adjust to 1.0 ml.
V umerjeno 1-mililitrsko brizgo za enkratno uporabo potegnite nekoliko več kot 1,0 ml sterilne vode za injekcije, nato pa volumen uravnajte na 1,0 ml.
In a study, after meningococcal and inactivated influenza vaccinations, a similar proportion of healthy volunteers treated with 150 mg of secukinumab and those treated with placebo were able to mount an adequate immune response of at least a 4-fold increase in antibody titres to meningococcal and influenza vaccines.
V študiji so zdravi prostovoljci, ki so prejeli 150 mg sekukinumaba, in tisti, ki so prejeli placebo, po prejemu meningokoknega cepiva in inaktiviranega cepiva proti gripi v približno enakem deležu razvili ustrezen imunski odziv z najmanj 4-kratnim porastom titrov protiteles proti meningokoknemu cepivu in cepivu proti gripi.
Anti-tuberculosis therapy should be considered prior to initiation of secukinumab in patients with latent tuberculosis.
Pri bolnikih z latentno tuberkulozo je treba pred začetkom uporabe sekukinumaba razmisliti o zdravljenju s tuberkulostatiki.
• The recommended dose is 300 mg by subcutaneous injection.
• Priporočeni odmerek je 300 mg s subkutano injekcijo.
This needle will only be used for withdrawing Cosentyx into the disposable syringe.
To iglo boste uporabili samo za to, da boste zdravilo Cosentyx potegnili v brizgo za enkratno uporabo.
For Psoriatic Arthritis study 3 (PsA study 3), the primary endpoint was at week 16 with the key secondary endpoint, the change from baseline in modified Total Sharp Score (mTSS), at week 24.
V 3. študiji psoriatičnega artritisa (PsA študiji 3) so primarni cilj opazovali po 16 tednih, ključni sekundarni cilj, to je spremembo modificirane skupne Sharpove ocene (mTSS - modified total Sharp Score) od izhodišča, pa po 24 tednih.
Note that foaming of the solution may occur.
Upoštevajte, da se raztopina pri tem lahko peni.
Insert the syringe needle into the vial containing the powder through the centre of the rubber stopper and reconstitute the powder by slowly injecting 1.0 ml of sterile water for injections into the vial.
Iglo brizge skozi sredino gumijaste zaporke vstavite v vialo, v kateri je prašek, in s počasnim injiciranjem 1,0 ml sterilne vode za injekcije v vialo rekonstituirajte prašek.
The European Medicines Agency has deferred the obligation to submit the results of studies with Cosentyx in plaque psoriasis in paediatric patients aged from 6 years to less than 18 years and in chronic idiopathic arthritis for paediatric patients aged from 2 years to less than 18 years (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Cosentyx pri psoriazi s plaki pri pediatričnih bolnikih v starostnem obdobju od 6 do manj kot 18 let in pri kroničnem idiopatskem artritisu pri pediatričnih bolnikih v starostnem obdobju od 2 do manj kot 18 let (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
• signs of low levels of white blood cells, such as fever, sore throat or mouth ulcers due to infections (neutropenia)
• znaki znižanega števila levkocitov, kot so zvišana telesna temperatura, vneto grlo oziroma žrelo ali razjede v ustih zaradi okužbe (nevtropenija),
Cosentyx is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label.
Zdravilo Cosentyx je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo, ki je vgrajena v peresnik trirobne oblike s prozornim okencem in nalepko.
Population pharmacokinetic analysis showed that secukinumab was absorbed with an average absolute bioavailability of 73% in patients with plaque psoriasis.
Rezultati analize populacijske farmakokinetike so pokazali, da se pri bolnikih s psoriazo s plaki sekukinumab absorbira s povprečno absolutno biološko uporabnostjo 73 %.
The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.
Večina protiteles IgG se izloča s pomočjo znotrajceličnega katabolizma po predhodnih procesih pinocitoze in receptorske endocitoze.
Be careful not to touch the syringe guard wings before use.
Pazite, da se pred odmerjanjem ne boste dotikali zapirala brizge.
How to use Cosentyx
Kako uporabljati zdravilo Cosentyx
The percentage of patients achieving ACR 20 response by visit is shown in Figure 2.
Na sliki 2 so po posameznih obiskih prikazani odstotki bolnikov, ki so dosegli odziv ACR 20.
Improvements in PASI 75 in patients with concurrent psoriatic arthritis at baseline were similar to those in the overall plaque psoriasis population.
Izboljšanje z odzivom PASI 75 pri bolnikih, ki so imeli ob izhodišču sočasno tudi psoriatični artritis, je bilo približno enako pogosto kot v celotni populaciji bolnikov s psoriazo s plaki.
Treatment with secukinumab resulted in significant improvement in measures of disease activity compared to placebo at weeks 16 and 24 (see Table 5).
Zdravljenje s sekukinumabom je povzročilo statistično značilno večje izboljšanje glede aktivnosti bolezni po 16 in 24 tednih v primerjavi s placebom (glejte preglednico 5).
Secukinumab was administered concomitantly with methotrexate (MTX), sulfasalazine and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis).
Sekukinumab so uporabljali sočasno z metotreksatom, sulfasalazinom in/ali kortikosteroidi v študijah artritisa (med drugim pri bolnikih s psoriatičnim artritisom in ankilozirajočim spondilitisom).
• Never try to reuse your pen.
• Že uporabljenega injekcijskega peresnika nikoli ne poskušajte ponovno uporabiti.
Following a single subcutaneous dose of 300 mg as a liquid formulation in healthy volunteers, secukinumab reached peak serum concentrations of 43.2±10.4 μg/ml between 2 and 14 days post dose.
Po enkratnem subkutanem odmerku 300 mg v tekoči obliki je sekukinumab pri zdravih prostovoljcih dosegel najvišjo koncentracijo v plazmi 43,2±10,4 μg/ml v času med 2. in 14. dnem po odmerjanju.
These instructions are to help you to inject correctly using the Cosentyx SensoReady pen.
Ta navodila vam bodo pomagala, da boste pri injiciranju zdravila Cosentyx pravilno uporabljali injekcijski peresnik SensoReady.
Similar responses were seen in PsA study 1 and efficacy was maintained up to week 52.
Podobne odzive so opažali v PsA študiji 1, učinkovitost zdravljenja pa se je ohranila do konca 52. tedna.
The mean volume of distribution during the terminal phase (Vz) following single intravenous administration ranged from 7.10 to 8.60 litres in plaque psoriasis patients, suggesting that secukinumab undergoes limited distribution to peripheral compartments.
Po odmerjanju enkratnega intravenskega odmerka je pri bolnikih s psoriazo s plaki povprečni volumen porazdelitve v terminalni fazi (Vz) znašal od 7,10 do 8,60 litra, kar kaže, da je porazdelitev sekukinumaba v prostor perifernih predelkov majhna.
Inject the Cosentyx solution subcutaneously into the front of thighs, lower abdomen (but not the area 5 centimetres around the navel) or outer upper arms.
Subkutano injicirajte raztopino zdravila na sprednjem delu stegen, na spodnjem delu trebuha (vendar ne v predelu, oddaljenem 5 centimetrov ali manj od popka) ali na zunanji strani nadlakti.
A placebo-controlled study evaluated 102 patients with moderate to severe scalp psoriasis, defined as having a Psoriasis Scalp Severity Index (PSSI) score of ≥12, an IGA mod 2011 scalp only score of 3 or greater and at least 30% of the scalp surface area affected.
V s placebom kontrolirani študiji so ocenjevali bolnike z zmerno do hudo psoriazo lasišča (102 bolnika), ki so imeli po opredelitvi indeks izraženosti psoriaze lasišča (PSSI - Psoriasis Scalp Severity Index) ≥12, oceno izraženosti psoriaze lasišča po modificirani oceni raziskovalca (IGA mod 2011) 3 ali več in prizadetih najmanj 30 % površine lasišča.
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with secukinumab developed antibodies to secukinumab up to 52 weeks of treatment.
V kliničnih študijah psoriaze, psoriatičnega artritisa in ankilozirajočega spondilitisa je pri manj kot 1% bolnikov, ki so prejemali sekukinumab, prišlo do razvoja protiteles proti sekukinumabu v obdobju do 52 tednov zdravljenja.
The condition is an inflammatory disease primarily affecting the spine which causes inflammation of the spinal joints.
Gre za vnetno bolezen, ki prizadeene zlasti hrbtenico in povzroča vnetje sklepov med vretenci.
Cosentyx is for long-term treatment.
Zdravljenje z zdravilom Cosentyx je dolgotrajno.
The single-use vial contains 150 mg secukinumab for reconstitution with sterile water for injections.
Viala za enkratno uporabo vsebuje 150 mg sekukinumaba, ki ga je treba rekonstituirati s sterilno vodo za injekcije.
Doses up to 30 mg/kg (approximately 2000 to 3000 mg) have been administered intravenously in clinical studies without dose-limiting toxicity.
V kliničnih študijah so bolnikom intravensko dajali odmerke do 30 mg/kg (približno 2.000 do 3.000 mg) in pri tem ni prišlo do toksičnega delovanja, zaradi katerega bi morali zmanjšati odmerjanje.
Cosentyx is used in adults with active ankylosing spondylitis.
Zdravilo Cosentyx uporabljamo pri odraslih z aktivnim ankilozirajočim spondilitisom.
• The recommended dose is 150 mg by subcutaneous injection.
• Priporočeni odmerek je 150 mg s subkutano injekcijo.
All patients received secukinumab 150 mg or 300 mg doses at weeks 0, 1, 2, 3, 4, 8 and 12 and then were randomised to receive either a maintenance regimen of the same dose every month starting at week 12 or a “retreatment as needed” regimen of the same dose.
Vsi bolniki so prejemali sekukinumab v odmerku 150 mg oziroma 300 mg v tednih 0, 1, 2, 3, 4, 8 in 12, nato pa so jih randomizirali tako, da so zdravilo prejemali bodisi po vzdrževalnem režimu v enakem odmerku enkrat na mesec z začetkom v 12. tednu ali pa po režimu "ponovitve zdravljenja po potrebi" z enakimi odmerki.
Most of the following side effects are mild to moderate.
Naslednji neželeni učinki so večinoma blago do zmerno izraženi.
The solution should be administered within one hour after removal from 2°C to 8°C storage.
Raztopino je treba aplicirati v roku 1 ure po premestitvi iz okolja s temperaturo med 2 °C in 8 °C.
9/l (CTCAE grade 3) was reported in 18 out of 3,430 (0.5%) patients on secukinumab, with no dose dependence and no temporal relationship to infections in 15 out of 18 cases.
9/l (stopnje 3 po Skupnih terminoloških kriterijih za neželene dogodke, CTCAE - Common Terminology Criteria for Adverse Events) so poročali pri 18 od 3.430 (0,5 %) bolnikov, ki so prejemali sekukinumab, pri tem pa pri 15 od 18 primerov reakcija ni bila niti odvisna od odmerka niti časovno povezana z okužbo.
Take the box containing the syringe out of the refrigerator and leave it unopened for about 15-30 minutes so that it reaches room temperature.
Škatlo z injekcijsko brizgo vzemite iz hladilnika in jo pustite zaprto približno 15-30 minut, da doseže sobno temperaturo.
To prepare Cosentyx 150 mg powder for solution for injection, please adhere to the following instructions:
Pri pripravljanju zdravila Cosentyx 150 mg prašek za raztopino za injiciranje upoštevajte naslednja navodila:
Exfoliative dermatitis Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA and AS patients exposed to 300 mg, 150 mg, 75 mg or placebo up to 12 weeks (psoriasis) or 16 weeks (PsA and AS) treatment duration Cases were reported in patients with psoriasis diagnosis
Bolezni kože in podkožja občasni urtikarija redki eksfoliativni dermatitis s placebom kontrolirane klinične študije (faze III) pri bolnikih s psoriazo s plaki, psoriatičnim artritisom oziroma ankilozirajočim spondilitisom, ki so prejemali odmerek 300 mg, 150 mg, 75 mg ali placebo v okviru zdravljenja, ki je trajalo do 12 tednov (pri psoriazi), ali 16 tednov (pri psoriatičnem artritisu oziroma ankilozirajočem spondilitisu) O primerih so poročali pri bolnikih z diagnozo psoriaze
If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function and slow down the damage to the cartilage and bone of the joints involved in the disease.
Če se na zdravljenje s temi zdravili ne bi dobro odzvali, boste dobili zdravilo Cosentyx za zmanjševanje znakov in simptomov aktivnega psoriatičnega artritisa, za izboljšanje telesne zmogljivosti in za zaviranje napredovanja okvar na hrustancu in kostnini v sklepih, ki so prizadeti zaradi bolezni.
Week 24 data are presented in Table 6.
V preglednici 6 so predstavljeni rezultati po 24 tednih zdravljenja.
Population pharmacokinetic analysis suggests that steady-state is reached after 20 weeks with monthly dosing regimens.
Rezultati analize populacijske farmakokinetike kažejo, da se stanje dinamičnega ravnovesja pri režimu odmerjanja enkrat na mesec vzpostavi po 20 tednih.
In the placebo-controlled period of clinical studies in plaque psoriasis (a total of 1,382 patients treated with secukinumab and 694 patients treated with placebo for up to 12 weeks), infections were reported in 28.7% of patients treated with secukinumab compared with 18.9% of patients treated with placebo.
V s placebom kontroliranih obdobjih kliničnih študij psoriaze s plaki (s skupno 1.382 bolniki, ki so do 12 tednov prejemali sekukinumab, in 694 bolniki, ki so prejemali placebo) so o okužbah poročali pri 28,7 % bolnikov, ki so prejemali sekukinumab, v primerjavi z 18,9 % bolnikov, ki so prejemali placebo.
Secukinumab-treated patients reported significant improvements in health-related quality of life as measured by the Short Form-36 Health Survey Physical Component Summary (SF-36 PCS) score (p<0.001).
Bolniki, ki so prejemali sekukinumab, so navajali statistično značilno povečanje ocene z zdravjem povezane kakovosti življenja po vprašalniku SF-36 PCS (SF-36 PCS - Short Form-36 Health Survey Physical Component Summary) (p<0,001).
Cosentyx is to be administered by subcutaneous injection.
Zdravilo Cosentyx je treba odmerjati s subkutano injekcijo.
Driving and using machines Cosentyx is unlikely to influence your ability to drive and use machines.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Cosentyx po vsej verjetnosti ne bo vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
ASDAS-CRP major improvement * p<0.05, ** p<0.01, *** p<0.001; versus placebo All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP
* p<0,05, ** p<0,01, *** p<0,001; v primerjavi s placebom Vse vrednosti p so prilagojene na večkratnost testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za BASDAI 50 in ASDAS-CRP.
The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3 mg/kg to 3x 10 mg/kg and with subcutaneous doses ranging from 1x 25 mg to multiple doses of 300 mg.
Farmakokinetiko sekukinumaba po odmerjanju enkratnega odmerka oziroma večkratnih odmerkov so pri bolnikih s psoriazo s plaki določali v več študijah z intravenskim odmerjanjem od 1x 0,3 mg/kg do 3x 10 mg/kg in v študijah s subkutanim odmerjanjem od 1x 25 mg do več odmerkov po 300 mg.
The condition is an inflammatory disease of the joints, often accompanied by psoriasis.
Gre za bolezen z vnetjem sklepov, ki ga pogosto spremlja še psoriaza (luskavica).
In PsA study 3, inhibition of progression of structural damage was assessed radiographically and expressed by the modified Total Sharp Score (mTSS) and its components, the Erosion Score (ES) and the Joint Space Narrowing Score (JSN).
V PsA študiji 3 so zaviranje napredovanja strukturnih okvar ocenjevali radiografsko in izrazili kot spremembo modificirane skupne Sharpove ocene (mTSS-modified total Sharp Score) in njenih komponent, ocene erozije sklepov in ocene zožitve sklepne špranje.
The ASAS 20 and ASAS 40 responses were maintained up to week 156 (69.5% and 47.6% for 150 mg versus 74.8% and 55.6% for 300 mg).
Odzivi ASAS 20 in ASAS 40 so se ohranili do 156. tedna (69,5 % in 47,6 % v skupini z odmerkom 150 mg v primerjavi s 74,8 % in 55,6 % v skupini z odmerkom 300 mg).
The 300 mg dose provided improved skin clearance particularly for “clear” or “almost clear” skin across the efficacy endpoints of PASI 90, PASI 100, and IGA mod 2011 0 or 1 response across all studies with peak effects seen at week 16, therefore this dose is recommended.
Odmerek 300 mg je v vseh študijah omogočal zmanjšanje prizadetosti kože zlasti v smislu ocen "brez znakov" ali "skoraj brez znakov" v okviru ciljev študije doseganja odziva PASI 90 oziroma PASI 100 ter odzivov IGA mod 2011 "0" oziroma "1", pri čemer so največji učinek opažali po 16 tednih zdravljenja, zato navedeni odmerek velja kot priporočeni odmerek.
In two additional placebo-controlled studies, improvement was seen in both nail psoriasis (TRANSFIGURE, 198 patients) and palmoplantar plaque psoriasis (GESTURE, 205 patients).
Specifična mesta prizadetosti/oblike psoriaze s plaki V dveh dodatnih s placebom kontroliranih študijah so opažali izboljšanje tako pri psoriazi s prizadetostjo nohtov (študija TRANSFIGURE, 198 bolnikov) kot pri palmoplantarni obliki psoriaze s plaki (študija GESTURE, 205 bolnikov).
• athlete's foot (tinea pedis)
• glivična okužba stopal (dermatofitija stopal, tinea pedis),
There were also statistically significant improvements demonstrated in exploratory endpoints assessed by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores for 150 mg and 300 mg compared to placebo (7.97, 5.97 versus 1.63, respectively) and these improvements were maintained up to week 104 in PsA study 2.
Dokazali so tudi statistično značilno izboljšanje pri raziskovalnih ciljih študije, ki so jih ocenjevali s pomočjo vprašalnika FACIT-F (FACIT-FFunctional Assessment of Chronic Illness Therapy - Fatigue) pri odmerjanju 150 mg in 300 mg zdravila v primerjavi s placebom (7,97 oziroma 5,97 v primerjavi z 1,63) in to izboljšanje se je v PsA študiji 2 ohranilo do konca 104. tedna.
The safety and efficacy of secukinumab were assessed in four randomised, double-blind, placebo-controlled phase III studies in patients with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy [ERASURE, FIXTURE, FEATURE, JUNCTURE].
Varnost in učinkovitost sekukinumaba so ocenjevali v štirih randomiziranih, dvojno slepih, s placebom kontroliranih študijah faze III pri bolnikih, ki so imeli zmerno do hudo psoriazo s plaki in so bili primerni za zdravljenje s fototerapijo ali sistemsko zdravljenje [študije ERASURE, FIXTURE, FEATURE in JUNCTURE].
Mean systemic clearance (CL) following a single intravenous administration to patients with plaque psoriasis ranged from 0.13 to 0.36 l/day.
Po odmerjanju enkratnega intravenskega odmerka bolnikom s psoriazo s plaki je povprečen sistemski očistek (CL) znašal od 0,13 do 0,36 l/dan.
All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week 16 for PsA study 3, except for ACR70 which was an exploratory endpoint and all endpoints at week 24.
V PsA študiji 3 so za teden 16 vse vrednosti p prilagojene na večkratnost testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za odziv ACR 70, ki je bil raziskovalni cilji študije, in za vse cilje študije za teden 24.
For all studies, the primary endpoint was American College of Rheumatology (ACR) 20 response.
V vseh študijah je bil primarni cilj študije odziv ACR 20 (20-odstotno izboljšanje po merilih Ameriške akademije za revmatologijo, ACR - American College of Rheumatology).
Renal impairment / hepatic impairment Cosentyx has not been studied in these patient populations.
Zdravila Cosentyx pri teh dveh skupinah bolnikov niso proučevali.
Remove the syringe from the outer box and take it out of the blister.
Injekcijsko brizgo vzemite iz zunanje škatle in iz pretisnega omota.